Assessing the Effects of Omega-3 Supplementation on Some Serum BDNF، Follistatin، Irisin Levels in Men With CAD
Assessing the Effects of Omega-3 Supplementation on Some Serum BDNF، Follistatin، Irisin Levels in Men With CAD
The aim of this study is the comparison between the effects of supplementation with omega 3
 or placebo for 8 weeks in serum level of BDNF، Follistatin، Irisin in patients with
 cardiovascular disease.
The aim of this study is the comparison between the effects of supplementation with omega 3
 or placebo for 8 weeks in serum level of BDNF، Follistatin، Irisin in patients with
 cardiovascular disease. In this randomized, double-blind clinical trial, placebo-controlled,
 single-center, and phase two trials, 42men aged 45-65 years with Coronary Artery Disease are
 enrolled in the study from Tehran Heart Center. After signing informed consent all
 individuals complete a general information form , 24-hour food recall for 3 days will be
 taken from the participants at the beginning and the end of the study,. Selected samples are
 randomly classified into 2 blocks of groups receiving supplement and placebo. The supplement
 group, will receive 4 g/day omega 3 fatty acid for 8 weeks and the placebo group will also
 receive placebo (containing 4 g of edible paraffin) (similar in terms of color, shape and
 size). Patients are recommended to sustain their diets and medication dose (s) during the
 study and also advised to maintain a constant level of physical activity. Blood samples will
 be collected after 8-12 hours fasting and anthropometric variables, biochemical parameters
 and physical activity before and after the trial will be measured.
Inclusion Criteria:

 -  cardiovascular disease patients 45- 65 years old,

 -  patients with ≥ 50% stenosis in at least one coronary angiogram demonstrated,

 -  body mass index in the range 18.5- 35,

 -  avoidance of dietary supplements, vitamins and herbal products at least 3 months
 before and throughout the intervention,

 -  willingness to participation,

 Exclusion Criteria:

 -  people who have used omega 3 supplements in last 3 months,

 -  having chronic renal disease ,

 -  GI disease,

 -  hepatobiliary diseases,

 -  hematological disorders,

 -  movement disorders,

 -  myopathy ,

 -  hypo- or hyperthyroidism,

 -  Smokers